Abstract
Several investigators including ourselves have shown that hydralazine can potentiate the anti-tumour activity of certain agents against murine tumours probably by manipulating tumour blood flow. In order to investigate the effects of administration of hydralazine on systemic and tumour drug concentrations, we have examined the plasma and tissue pharmacokinetics of the recently developed nitrosourea, Tauromustine (TCNU). The effect of hydralazine on glomerular filtration rate (GFR) in mice was also examined using inulin single injection plasma clearance. An active dose of TCNU (30 mg kg-1) was administered intravenously into non-tumour bearing NMRI mice or mice bearing MAC 15A or MAC 26 subcutaneous tumours. Plasma and tissue levels of TCNU were measured by HPLC. Hydralazine significantly increased (P less than .005 in all cases) the AUCs and decreased the plasma clearance of the drug. Inulin plasma clearance was decreased from 0.258 +/- 0.046 ml min-1 to 0.096 +/- 0.017 ml min-1 (a factor of 2.69) after administration of hydralazine. This decrease in GFR would explain the increased plasma half-lives of a renally cleared drug. It is likely that the increased AUC values are partly responsible for the improved anti-tumour activity of TCNU when administered with hydralazine, but the impact of these findings on toxicity needs to be established.
Highlights
It has long been known that perfusion of experimental tumours can be manipulated by the use of vasoactive agents (Algire & Legallais. 1951)
Inulin plasma clearance was decreased from 0.258 ± 0.046 ml min-' to 0.096 ± 0.017 ml min-' after administration of hydralazine
It is likelv that the increased AUC values are partly responsible for the improved anti-tumour activity of TCNU when administered with hydralazine. but the impact of these findings on toxicity needs to be established
Summary
Pure strain NMRI mice (6-8 weeks of age) were used from our inbred colony. Received 22 August 1991: and in revised form 13 November 1991. Were carried out under a Project Licence approved by the Home Office.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.